Skip to main content

PALISADE BIO, INC.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

PALI$1.19+5.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

ance Sheets (Unaudited)

(in thousands, except share and per share amounts)

June 30,December 31,
20252024
ASSETS
Current assets:
Cash and cash equivalents$5,417$9,821
Prepaid expenses and other current assets1,030673
Total current assets6,44710,494
Restricted cash2626
Property and equipment, net13
Operating lease right-of-use asset2284
Other noncurrent assets171273
Total assets$6,667$10,880
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$1,374$1,105
Accrued liabilities2,0661,240
Accrued compensation and benefits192722
Current portion of operating lease liability2490
Insurance financing debt31479
Total current liabilities3,9703,236
Warrant liability22
Contingent consideration obligation75150
Total liabilities4,0473,388
Commitments and contingencies (Note 9)
Stockholders' equity:
Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at June 30, 2025 and December 31, 202422
Common stock, $0.01 par value; 280,000,000 shares authorized;4,800,247 and 2,768,646 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively4827
Additional paid-in capital143,528143,407
Accumulated deficit(140,958)(135,944)
Total stockholders' equity2,6207,492
Total liabilities and stockholders' equity$6,667$10,880
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.